Prednisolone
- Generic Name
- Prednisolone
- Brand Names
- Millipred Dp 6 Day
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28O5
- CAS Number
- 50-24-8
- Unique Ingredient Identifier
- 9PHQ9Y1OLM
- Background
Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.
Prednisolone was granted FDA approval on 21 June 1955.
- Indication
Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- -
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1046
- Registration Number
- NCT06717347
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 16
- Registration Number
- NCT06676579
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Target Recruit Count
- 100
- Registration Number
- NCT06654934
- Locations
- 🇮🇳
Post Graduate Institute of Medical Education and Research, Chandigarh, India
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT06624670
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇨🇦University of Alberta Hospital (University of Alberta), Edmonton, Alberta, Canada
🇨🇦Centre de Recherche Saint-Louis, Quebec, Canada
R-CMOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Qiu Lugui
- Target Recruit Count
- 108
- Registration Number
- NCT06594640
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Renata PLC
- Target Recruit Count
- 100
- Registration Number
- NCT06531018
- Locations
- 🇧🇩
Dhaka Medical College Hospital, Dhaka, Bangladesh
A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Gene Therapies
- Target Recruit Count
- 14
- Registration Number
- NCT06483802
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Institut Cancerologie de l'Ouest
- Target Recruit Count
- 84
- Registration Number
- NCT06471465
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest, Saint-Herblain, France
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06421597
- Locations
- 🇩🇰
Hospital of South West Jutland, Esbjerg, Denmark
🇩🇰Odense University Hospital, Odense C, Denmark
Ma-Spore ALL 2020 Study
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT06336395
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.